Invitrogen™ Neisseria gonorrhoeae Monoclonal Antibody (6144)

Description

Specificity: Reactive with all strains of N. gonorrhoeae tested. Reactive with: 9 strains of N. gonorrhoeae, N. lactamica & N. meningitidis. Non-reactive with: N. mucosa, N. perflava, N. sicca, Gardnerella vaginalis, group B Streptococcus, Candida albicans, Hemophilus influenza type B, Chlamydia trachomatis, Trichomonas vaginalis, Mycoplasma genitalium, Ureaplasma urealyticum & Herpes simplex virus type 2. Purified preparations consist of >90% pure mouse monoclonal antibody which has been purified from ascites fluid by protein A chromatography. The final preparation is formulated to a protein concentration of 100 μg/mL in 0.01 M phosphate buffered saline, pH 7.2 and contains 0.1% sodium azide. Each vial contains 1.0 mL. This product contains no stabilizing proteins and should be stored at 4C until ready for use. Working dilution must be determined by the user. Suggested starting ranges are 1:10-1:50 for ICC/IF and 1:20-1:200. for ELISA.

Although pathogenic bacteria constitute only a small portion of bacterial species, infectious diseases caused by pathogenic bacteria affect millions of people worldwide. Diarrheal diseases, many of which are bacterial, are the second leading cause of death worldwide, claiming an estimated 5 million people annually. Furthermore, an estimated 3 million people die of tuberculosis annually, 500,000 people die of pertussis, and 25,000 die of typhoid. The ability of bacteria to utilize various food sources is a major factor behind their pervasiveness. Their vast numbers lead to rapid evolutionary changes resulting in emerging diseases as well as antibiotic-resistant strains of well known diseases. Examples of these are multi-drug resistant tuberculosis and methicillin-resistant Staphylococcus aureus. Research into the detection and treatment of these infectious disease agents will continue to expand in an effort to alleviate the effects of these diseases.